Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

Daniele Santini, Matteo Santoni, A. Conti, Giuseppe Procopio, Elena Verzoni, Luca Galli, Giuseppe Di Lorenzo, Ugo De Giorgi, Delia De Lisi, M. Nicodemo, Marco Maruzzo, Francesco Massari, Sebastiano Buti, Emanuela Altobelli, Elisa Biasco, Riccardo Ricotta, Camillo Porta, Bruno Vincenzi, Rocco Papalia, Paolo Marchetti & 6 others L. Burattini, R. Berardi, G. Muto, Rodolfo Montironi, Stefano Cascinu, Giuseppe Tonini

Research output: Contribution to journalArticle

Abstract

PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37% patients achieve CR with TKI alone, while 63% with additional loco-regional treatments. 49% patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40% vs 61%) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastasis (50%). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.NS: The prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.

Original languageEnglish
Pages (from-to)33381-33390
Number of pages10
JournalOncotarget
Volume7
Issue number22
DOIs
Publication statusPublished - May 31 2016

Fingerprint

Renal Cell Carcinoma
Recurrence
Survival
Disease-Free Survival
Phosphotransferases
Therapeutics
Combined Modality Therapy
Neoplasm Metastasis
Bone and Bones
Brain

Keywords

  • Complete responder patients
  • Conditional survival
  • Renal cell carcinoma
  • Risk of recurrence
  • Tirosin kinase inhibitor

ASJC Scopus subject areas

  • Oncology

Cite this

Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. / Santini, Daniele; Santoni, Matteo; Conti, A.; Procopio, Giuseppe; Verzoni, Elena; Galli, Luca; Di Lorenzo, Giuseppe; De Giorgi, Ugo; De Lisi, Delia; Nicodemo, M.; Maruzzo, Marco; Massari, Francesco; Buti, Sebastiano; Altobelli, Emanuela; Biasco, Elisa; Ricotta, Riccardo; Porta, Camillo; Vincenzi, Bruno; Papalia, Rocco; Marchetti, Paolo; Burattini, L.; Berardi, R.; Muto, G.; Montironi, Rodolfo; Cascinu, Stefano; Tonini, Giuseppe.

In: Oncotarget, Vol. 7, No. 22, 31.05.2016, p. 33381-33390.

Research output: Contribution to journalArticle

Santini, D, Santoni, M, Conti, A, Procopio, G, Verzoni, E, Galli, L, Di Lorenzo, G, De Giorgi, U, De Lisi, D, Nicodemo, M, Maruzzo, M, Massari, F, Buti, S, Altobelli, E, Biasco, E, Ricotta, R, Porta, C, Vincenzi, B, Papalia, R, Marchetti, P, Burattini, L, Berardi, R, Muto, G, Montironi, R, Cascinu, S & Tonini, G 2016, 'Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma', Oncotarget, vol. 7, no. 22, pp. 33381-33390. https://doi.org/10.18632/oncotarget.8302
Santini, Daniele ; Santoni, Matteo ; Conti, A. ; Procopio, Giuseppe ; Verzoni, Elena ; Galli, Luca ; Di Lorenzo, Giuseppe ; De Giorgi, Ugo ; De Lisi, Delia ; Nicodemo, M. ; Maruzzo, Marco ; Massari, Francesco ; Buti, Sebastiano ; Altobelli, Emanuela ; Biasco, Elisa ; Ricotta, Riccardo ; Porta, Camillo ; Vincenzi, Bruno ; Papalia, Rocco ; Marchetti, Paolo ; Burattini, L. ; Berardi, R. ; Muto, G. ; Montironi, Rodolfo ; Cascinu, Stefano ; Tonini, Giuseppe. / Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 22. pp. 33381-33390.
@article{cbb44afe43e049dc9e1f9b3450e3981f,
title = "Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma",
abstract = "PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37{\%} patients achieve CR with TKI alone, while 63{\%} with additional loco-regional treatments. 49{\%} patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40{\%} vs 61{\%}) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88{\%}), pancreatic (71{\%}) and bone metastasis (50{\%}). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.NS: The prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.",
keywords = "Complete responder patients, Conditional survival, Renal cell carcinoma, Risk of recurrence, Tirosin kinase inhibitor",
author = "Daniele Santini and Matteo Santoni and A. Conti and Giuseppe Procopio and Elena Verzoni and Luca Galli and {Di Lorenzo}, Giuseppe and {De Giorgi}, Ugo and {De Lisi}, Delia and M. Nicodemo and Marco Maruzzo and Francesco Massari and Sebastiano Buti and Emanuela Altobelli and Elisa Biasco and Riccardo Ricotta and Camillo Porta and Bruno Vincenzi and Rocco Papalia and Paolo Marchetti and L. Burattini and R. Berardi and G. Muto and Rodolfo Montironi and Stefano Cascinu and Giuseppe Tonini",
year = "2016",
month = "5",
day = "31",
doi = "10.18632/oncotarget.8302",
language = "English",
volume = "7",
pages = "33381--33390",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "22",

}

TY - JOUR

T1 - Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma

AU - Santini, Daniele

AU - Santoni, Matteo

AU - Conti, A.

AU - Procopio, Giuseppe

AU - Verzoni, Elena

AU - Galli, Luca

AU - Di Lorenzo, Giuseppe

AU - De Giorgi, Ugo

AU - De Lisi, Delia

AU - Nicodemo, M.

AU - Maruzzo, Marco

AU - Massari, Francesco

AU - Buti, Sebastiano

AU - Altobelli, Emanuela

AU - Biasco, Elisa

AU - Ricotta, Riccardo

AU - Porta, Camillo

AU - Vincenzi, Bruno

AU - Papalia, Rocco

AU - Marchetti, Paolo

AU - Burattini, L.

AU - Berardi, R.

AU - Muto, G.

AU - Montironi, Rodolfo

AU - Cascinu, Stefano

AU - Tonini, Giuseppe

PY - 2016/5/31

Y1 - 2016/5/31

N2 - PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37% patients achieve CR with TKI alone, while 63% with additional loco-regional treatments. 49% patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40% vs 61%) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastasis (50%). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.NS: The prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.

AB - PURPOSE: We retrospectively analyzed the risk of recurrence and conditional Disease-Free Survival (cDFS) in 63 patients with complete remission during treatment with tirosin kinase inhibitor (TKI), alone or with local treatment in metastatic renal cell carcinoma. RESULTS: 37% patients achieve CR with TKI alone, while 63% with additional loco-regional treatments. 49% patients recurred after CR, with a median Disease free survival of 28.2 months. Patients treated with multimodal approaches present lower rate of recurrence (40% vs 61%) and longer Disease free survival compared to patient treated with TKI alone (16.5 vs 41.9 months, p=0.039).Furthermore the rate of recurrence was higher in patients with brain (88%), pancreatic (71%) and bone metastasis (50%). Patients who continued TKI therapy after complete response had a longer disease free survival than patients who stopped therapy, although the difference was not significant (42.1 vs 25.1 months, p=0.254). 2y-cDFS was better in patients treated with multimodal treatment and who continued TKIs than the other patient arms.NS: The prognostic value of CR depends on the site where was obtained and how was obtained (with or without locoregional treatment). Cessation of TKI should be carefully considered in complete responder patients.

KW - Complete responder patients

KW - Conditional survival

KW - Renal cell carcinoma

KW - Risk of recurrence

KW - Tirosin kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84973541350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973541350&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8302

DO - 10.18632/oncotarget.8302

M3 - Article

VL - 7

SP - 33381

EP - 33390

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -